Getinge AB

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: SE0000202624
SEK
210.70
192.6 (1064.09%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Getinge AB stock-summary
stock-summary
Getinge AB
Pharmaceuticals & Biotechnology
Getinge AB is a Sweden-based company active in the healthcare sector. It provides products and services for intensive care units, sterilization centers, elderly care and companies and institutions active in the life sciences area. Its operations are divided into three business areas: The Medical Systems business area offers equipment for surgical disciplines, cardiology and intensive care; the Extended Care business area offers products and services geared toward the hospital and elderly care markets, including solutions for preventing the risk of pressure ulcers and deep vein thrombosis, and the Infection Control business area features systems for preventing the occurrence and spread of infection. Its products comprise disinfectors, sterilizers, including low temperature sterilization solutions, information technology (IT) solutions, as well as advice, training and technical support. The Company's products are sold under the Getinge, Lancer, ArjoHuntleigh and MAQUET brands.
Company Coordinates stock-summary
Company Details
Ekebergsvagen 26,, P.O. Box 69 GOETEBORG None : 305 75
stock-summary
Tel: 46 3 515550046 10 3350043
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.32%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Johan Malmquist
Chairman of the Board
Mr. Mattias Perjos
President, Chief Executive Officer, Director
Mr. Carl Bennet
Vice Chairman of the Board
Mr. Dan Frohm
Director
Mr. Peter Jormalm
Director, Representative of Unionen
Mr. Rickard Karlsson
Director, Representative of Swedish Metalworkers Union Assembly
Mr. Johan Bygge
Independent Director
Dr. Barbro Friden
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
8,238 Million
(Quarterly Results - Jun 2025)
Net Profit:
527 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

SEK 55,837 Million (Mid Cap)

stock-summary
P/E

25.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

2.09%

stock-summary
Debt Equity

0.26

stock-summary
Return on Equity

9.55%

stock-summary
Price to Book

1.91